Peptide therapeutics companies develop medicines built from short chains of amino acids designed to interact with specific biological targets. These molecules can combine high target selectivity with formats suited to a wide range of therapeutic applications.
This category includes companies working on:
Browse 41 UK peptide therapeutics companies below.
Phase 3 urcosimod therapy for neuropathic corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing topical therapies for neuropathic corneal pain and other ocular surface conditions. Its lead candidate, urcosimod (formerly OK-101), is a chemerin receptor agonist designed to modulate inflammation and corneal pain signalling. Phase 2a testing…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule scaffold into two loops, conferring high-affinity target binding with the tissue penetration of small molecules. Its lead programme, a…
Manufacturer of small molecule and peptide reagents for life science research
Tocris Bioscience is a manufacturer and supplier of high-purity small molecule and peptide research reagents serving the global life science community. Its catalogue of over 4,500 products includes receptor agonists and antagonists, ion channel modulators, enzyme inhibitors, signalling pathway tools, and fluorescent…
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…
Cyclic peptide screening platform for first-in-class cancer drugs
Curve Therapeutics is a drug discovery company using its proprietary platform to identify first-in-class small molecule therapeutics against targets that have been difficult to address using conventional methods. The platform screens gene-encoded cyclic peptide libraries inside mammalian cells to identify functionally…
Engineered bacterial nanosyringes for intracellular protein delivery
NanoSyrinx is a discovery-stage biotechnology company developing a platform for targeted intracellular delivery of protein and peptide therapeutics. Based on naturally occurring bacterial nanomachines, the company's technology is engineered to deliver biological payloads directly to the cytosol of targeted cells…
GMP biomanufacturing and biopharmaceutical development services
Ab Biotechnology is a UK-based contract development and manufacturing organisation providing process development, assay development and GMP manufacturing services for biopharmaceutical products. The company offers protein production, peptide synthesis, purification, analytical testing and small-scale GMP manufacture…
Contract pharmaceutical development, manufacturing and diagnostic services
Almac Group is a privately owned contract development and manufacturing organisation providing integrated services across the drug development lifecycle to pharmaceutical and biotechnology clients. Capabilities span API and peptide synthesis, formulation development, GMP clinical and commercial manufacturing, clinical…
Precision oncology drugs and vaccines for cold tumours
IngenOx Therapeutics Limited is a clinical-stage biopharmaceutical company developing precision oncology drugs and cancer vaccines for difficult-to-treat tumours. The company serves oncology patients and clinical development partners through a pipeline spanning small molecule immunomodulators, PRMT5 inhibition and…
Preclinical inhibitors of Notch and Mastermind cancer signalling pathways
Anastasis Biotec is a preclinical biotechnology company developing targeted inhibitors of cancer signalling pathways, with a focus on the Notch pathway and its transcriptional co-activator Mastermind. These pathways help drive tumour growth and the survival of cancer stem cells. The company is developing peptide-based…
AI-driven protein interaction modelling for peptide drug discovery
Xenos Bio is developing a computational platform that uses physics-based algorithms integrated with machine learning to predict protein-protein interactions and identify binding motifs within functional protein domains. Its software is deployed for rational peptide library construction, delivering enhanced hit…
Engineered probiotic bacteria producing peptide therapeutics inside the body
Hijack Bio develops engineered probiotic bacteria designed to produce and release peptide therapeutics inside the body. The synthetic biology approach aims to reduce reliance on conventional external manufacturing and cold-chain distribution while enabling oral delivery of peptide drugs. Potential applications include…
Long-acting GnRH antagonist for prostate cancer and urinary retention
Antev is a clinical-stage biopharmaceutical company developing a long-acting gonadotropin-releasing hormone (GnRH) antagonist that suppresses testosterone production. Its lead peptide therapy is being developed for men with advanced prostate cancer, including those at high cardiovascular risk, and for men experiencing…
Experimental diabetes research into insulin and metabolic therapies
Centre for Diabetes is an Ulster University research centre in Coleraine investigating the molecular mechanisms of diabetes and emerging treatment approaches. Its research includes pancreatic beta-cell dysfunction, insulin secretion, glycation, glucose-regulating peptides and experimental antidiabetic compounds. The…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The technology enables precision delivery to the colon for local and systemic immunomodulation, targeting gastrointestinal and systemic…
Proprietary formulation platform enhancing diabetes and cardiometabolic therapies
Arecor Therapeutics is a biopharmaceutical company developing enhanced formulations of existing therapeutic products for diabetes and cardiometabolic diseases. Its proprietary formulation technology improves stability, concentration and delivery profiles for biologics and peptides, supporting both in-house programmes…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Clinical-stage anti-infectives targeting antimicrobial resistance and infectious disease
NovaBiotics is a clinical-stage biotechnology company developing first-in-class anti-infective therapies for difficult-to-treat infectious diseases, with a focus on antimicrobial resistance. Its pipeline is built on two proprietary platforms: an anti-infective peptide platform yielding antifungal and antibacterial…
Sustained-release ocular drug delivery for retinal disease
Re-Vana Therapeutics is a biotechnology company developing sustained-release drug delivery technologies for the treatment of serious retinal diseases. Its biodegradable hydrogel platform uses photo-crosslinking to form in-situ implants administered via intravitreal injection, enabling controlled release of biologics,…